Previous close | 7.50 |
Open | 8.30 |
Bid | 8.40 |
Ask | 8.50 |
Strike | 100.00 |
Expiry date | 2023-06-16 |
Day's range | 8.30 - 8.45 |
Contract range | N/A |
Volume | |
Open interest | 7.1k |
Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely. Western drugmakers including Pfizer Inc, BioNTech SE, Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022. Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most.
Merck ( NYSE:MRK ) Full Year 2022 Results Key Financial Results Revenue: US$59.3b (up 22% from FY 2021). Net income...
AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.